Analyst Price Target is $9.00
▲ +246.15% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Praxis Precision Medicines in the last 3 months. The average price target is $9.00, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 246.15% upside from the last price of $2.60.
Current Consensus is
Buy
The current consensus among 4 contributing investment analysts is to buy stock in Praxis Precision Medicines. This rating changed within the last month from a Hold consensus rating.
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depression; and PRAX-944, a selective small molecule inhibitor of T-type calcium channels, which is in Phase IIa clinical trial for the treatment of essential tremor. The company is also developing PRAX-562, a persistent sodium current blocker that is in Phase I clinical trial to treat severe pediatric epilepsy and adult cephalgia; PRAX-222, an antisense oligonucleotide (ASO) for patients with gain-of-function (GOF) SCN2A epilepsy; and KCNT1 program for the treatment of KCNT1 GOF epilepsy. It has a cooperation and license agreement with RogCon Inc.; a license agreement with Purdue Neuroscience Company; a research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.
Read More
